Women with previously untreated advanced disease after surgery were randomly allocated to six cycles of platinum-taxane chemotherapy plus placebo cycles ( C ) 2 to C22 ( R1 ) ; chemotherapy plus bevacizumab C2 to C6 plus placebo C7 to C22 ( R2 ) ; or chemotherapy plus bevacizumab C2 to C22 ( R3 ) .